Prostatic artery embolization is a minimally invasive procedure performed to treat symptoms caused by an enlarged prostate or benign prostatic hyperplasia (BPH). It involves blocking the blood vessels that supply the prostate gland to reduce its size. With advancing age, the chances of developing BPH increases as the prostate gland enlarges. This frequently causes symptoms such as difficulty urinating, urine retention, and urgency. The procedure provides rapid and long lasting relief from BPH symptoms and prevents the need for medications or surgery in many patients. The global prostatic artery embolization market is estimated to be valued at US$ 235 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
The growing geriatric population is a major driver of the prostatic artery embolization market. Over time, the chances of suffering from BPH rise significantly with age. By 2030, approximately 1.5 billion people will be aged 65 years or older according to the World Health Organization (WHO). An aging population base means a higher demand for minimally invasive procedures like prostatic artery embolization used to treat BPH symptoms. As people continue to live longer, more individuals will develop enlarged prostates over their lifetime. This offers considerable untapped market potential for prostatic artery embolization procedures aimed at improving quality of life in elderly men. Increased access to and awareness about the benefits of the procedure over medications and surgery can help address the needs of this expanding demographic in upcoming years.

Porter’s Analysis
Threat of new entrants: The prostatic artery embolization market has moderate threat from new entrants due to high capital investment needs for R&D and clinical approval of new medical devices and therapies. However, the growing patient pool suffering from BPH and low penetration of minimally invasive treatments offer opportunities.
Bargaining power of buyers: The bargaining power of buyers is moderate as the demand for effective and less invasive BPH treatments is growing. However, the availability of alternative treatment options provides some bargaining power.
Bargaining power of suppliers: The bargaining power of suppliers is moderate given the presence of several medical device suppliers and availability of substitutes. Suppliers differ based on device design, delivery systems and catheter technologies.
Threat of new substitutes: The threat of substitutes is moderate as other minimally invasive procedures for BPH like transurethral needle ablation and transurethral microwave therapy provide competition.
Competitive rivalry: The competitive rivalry is high due to the presence of large global players and steady approvals of new products.

SWOT Analysis
Strength: Prostatic artery embolization is a minimally invasive outpatient procedure with benefits like quicker recovery time and lesser complications compared to TURP. Rising geriatric population suffering from BPH drives the demand.
Weakness: Steep learning curve for clinicians, lack of long-term data on efficacy and safety, and reimbursement issues in some regions restricts market growth.
Opportunity: Low penetration of minimally invasive treatments for BPH presents lucrative opportunities. Strategic collaborations for product innovations will aid market expansion in untapped regions.
Threats: Strong dependence on reimbursement policies, social stigma around discussing men's health issues in developing nations. Complications and device failures remain major challenges.

Key Takeaways
The Global Prostatic Artery Embolization Market Size is expected to witness high growth during the forecast period. The double-digit CAGR of 12% is anticipated due to growing geriatric population, preference of minimally invasive techniques over surgery, and new product approvals.

Regional Analysis: North America currently dominates the global market owing to rising healthcare expenditures, highly developed healthcare systems, and increasing adoption of advanced BPH treatments. According to estimates, the region accounted for over 40% of the total market share in 2023.

Key players operating in the prostatic artery embolization market are Ingersoll-Rand plc (Nexia), Vivint, Inc., Protection One Alarm Monitoring, Inc., The ADT Corporation, Telus Communications, Frontpoint Security Solutions, AT&T Inc., Johnson Controls, Inc., Comcast Corporation, Charter Communications (TWC), and CenturyLink, Inc. Leading players are investing in developing advanced catheter technologies and delivery systems to expand their product portfolio and market presence globally. Partnerships with larger medical equipment providers also aid commercialization of prostatic artery embolization devices.

For More Insights, Read: https://www.trendingwebwire.com/prostatic-artery-embolization-market-size-share-and-growth-forecast-2024-2030/